FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
Snapshot: PEG-MGF (PEGylated Mechano-Growth Factor) is a regulated IGF-1 Ec-derived peptide used in preclinical research to study IGF-1R, PI3K/Akt, and MAPK/ERK signaling in tissue-repair and regeneration models. Experimental studies have explored its roles in skeletal muscle recovery, periodontal ligament remodeling, bone and cartilage repair, and injury-response pathways.
PEG-MGF (Polyethylene Glycol–Modified Mechano-Growth Factor) is a chemically-modified peptide related to the IGF-1 Ec splice-variant sequence (also called MGF). In research settings, it is used as a pathway probe to study IGF-axis signaling, skeletal muscle regeneration programs, and injury-response biology in both in vitro and in vivo models [1, 2, 3]. Pegylation is applied to increase peptide persistence and stability, allowing for longer exposure windows compared with non-pegylated fragments in time-course and distribution studies [4].
Experimental studies most often evaluate PEG-MGF in contexts including skeletal muscle injury and repair, cardiac ischemia and hypoxia, bone healing and osteoblast activity, cartilage and chondrocyte migration, and periodontal ligament cell differentiation. Mechanistically, its actions are linked to IGF-1 receptor activation and downstream PI3K/Akt and MAPK/ERK signaling pathways, which are associated with cell growth, migration, and survival responses [3].
PEG-MGF has been investigated in preclinical and mechanistic research models, with findings suggesting potential roles in muscle repair and regeneration [5], modulation of inflammatory mediator expression and immune-cell clearance kinetics [6], osteoblast proliferation [7], chondrocyte migration and mechanotransduction pathways [2], and apoptosis and remodeling in cardiac injury models [8].
In experimental settings, key considerations include the fact that IGF-axis activation is linked to cell-proliferation signaling, which warrants caution in models involving abnormal or uncontrolled cell growth [2]. Effects may also vary depending on delivery method and PEGylation format, and current evidence remains largely limited to controlled preclinical studies. These findings are model-specific and should be interpreted within a lab-research context.
PEG-MGF and related MGF-derived peptides are frequently studied in models of muscle injury and repair. These experiments typically measure changes in inflammation, oxidative stress, and expression of genes involved in tissue recovery and remodelling [2]. Cell-based studies using myoblasts and muscle-cell cultures also study cell growth, migration, and IGF-1R-linked PI3K/Akt and MAPK/ERK signaling, which are pathways associated with hypertrophy and regeneration rather than performance enhancement [2].
Across multiple studies, MGF peptides support satellite-cell activation, proliferation, and fusion, which are key steps in muscle maintenance and repair [5, 3]. In primary human muscle cell cultures, the MGF-24aa-E peptide increased the proliferative lifespan of satellite cells and delayed cellular aging in younger tissue, while promoting hypertrophy across all age groups [5]. These effects are interpreted as enhanced regenerative capacity, particularly relevant to age-related muscle loss and sarcopenia [5]. Other experimental models show that early increases in MGF splice-variant expression tend to coincide with the initial, proliferation-focused phase of muscle repair, followed later by differentiation and myofiber maturation [3].
MGF-related peptides have also been studied in cardiac injury settings. In animal models of myocardial infarction, delivery of MGF E-domain peptides has been associated with better preservation of cardiac function, smaller regions of compromised tissue, reduced cell-death signaling, and slower progression of adverse remodeling [8, 9]. In some studies, localized delivery using peptide-eluting biomaterial structures further improved hemodynamic recovery following injury [9].
Overall findings suggest benefits for repair, survival, and regeneration-linked signaling programs both in skeletal and cardiac muscle, with applications focused on tissue-healing rather than performance outcomes.
MGF-related peptides have also been studied in periodontal ligament (PDL) regeneration models, particularly under mechanical loading conditions such as occlusal force.
In vitro and in vivo studies show that MGF produced in response to mechanical stimulation can enhance PDL remodelling and promote periodontal ligament stem-cell proliferation and fibrogenic differentiation [10, 11]. These effects are linked to Fyn-FAK-mediated mechanochemical signaling, activation of ERK1/2 and p38 pathways, and the Fyn-RhoA-YAP phosphorylation axis, which together support matrix remodeling and fibroblast-like differentiation [10].
Collectively, these findings suggest a potential role for MGF-centered signaling as an adjunct approach in periodontal regeneration research.
PEG-MGF peptides have been studied in multiple injury- and regeneration-focused models. In cardiac ischemia, MGF expression rises rapidly and peptide delivery has been associated with reduced apoptosis, preservation of myocardium, improved hemodynamics, and possible stimulation of precursor cell recruitment [4].
In neural and hypoxia-ischemia models, MGF shows neuroprotective activity independent of IGF-1R signaling, supporting cell survival pathways [4]. MGF has also been reported to influence chondrocyte and mesenchymal-cell differentiation, matrix remodelling, and cytoskeletal dynamics under stress or damage conditions [4].
References
1 Liu, X., Zeng, Z., Zhao, L., Chen, P. and Xiao, W. (2019) Impaired skeletal muscle regeneration induced by macrophage depletion could be partly ameliorated by MGF injection. Front. Physiol., Frontiers Media SA 10, 601
2 Liu, Y., Duan, M., Zhang, D. and Xie, J. (2023) The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta Biochim. Biophys. Sin. (Shanghai), China Science Publishing & Media Ltd. 55, 701–712
3 Matheny, R. W., Jr, Nindl, B. C. and Adamo, M. L. (2010) Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology, The Endocrine Society 151, 865–875
4 Zabłocka, B., Goldspink, P. H., Goldspink, G. and Górecki, D. C. (2012) Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front. Endocrinol. (Lausanne), Frontiers Media SA 3, 131
5 Kandalla, P. K., Goldspink, G., Butler-Browne, G. and Mouly, V. (2011) Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech. Ageing Dev. 132, 154–162
6 Lin, Y.-C., Chen, B.-M., Tran, T. T. M., Chang, T.-C., Al-Qaisi, T. S. and Roffler, S. R. (2023) Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. J. Control. Release, Elsevier BV 354, 354–367
7 Deng, M., Zhang, B., Wang, K., Liu, F., Xiao, H., Zhao, J., et al. (2011) Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. Int. Orthop., Springer Science and Business Media LLC 35, 1099–1106
8 Carpenter, V., Matthews, K., Devlin, G., Stuart, S., Jensen, J., Conaglen, J., et al. (2008) Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ., Elsevier BV 17, 33–39
9 Peña, J. R., Pinney, J. R., Ayala, P., Desai, T. A. and Goldspink, P. H. (2015) Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction. Biomaterials, Elsevier BV 46, 26–34
10 Feng, F., Tu, T., Wang, H., Song, R., Li, J., Zhu, Y., et al. (2024) Mechano-growth factor regulates periodontal ligament stem cell proliferation and differentiation through Fyn-RhoA-YAP signaling. Biochem. Biophys. Res. Commun., Elsevier BV 733, 150450
11 Zhao, Y., Zhang, S., Cheng, B., Feng, F., Zhu, Y., Liu, Y., et al. (2024) Mechanochemical coupling of MGF mediates periodontal regeneration. Bioeng. Transl. Med., Wiley 9, e10603
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). PEG-MGF is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
